A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Trial Status

Current Trial - Enrollment Complete

Sponsor:

GlaxoSmithKline

Researchers:

Cristine Berry, MD, MHS

Research Specialties:

Pulmonary

Link:

Clinicaltrials.gov

Link to Study

https://clinicaltrials.gov/ct2/show/NCT02164513?term=NCT02164513&rank=1

Principal Investigator(s)

Lynn B. Gerald, PhD, MSPH

Research Area

Applied and Basic Research

Disease Type

Chronic Obstructive Pulmonary Disease (COPD)

keyboard_arrow_up Back to top